Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Am J Physiol Renal Physiol ; 325(1): F121-F133, 2023 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-37167274

RESUMEN

Transforming growth factor (TGF)-ß1 contributes to podocyte injury in various glomerular diseases, including diabetic kidney disease, probably at least in part by attenuating the expression of Wilms' tumor 1 (WT1). However, the precise mechanisms remain to be defined. We performed miRNA microarray analysis in a human podocyte cell line cultured with TGF-ß1 to examine the roles of miRNAs in podocyte damage. The microarray analysis identified miR-143-3p as the miRNA with the greatest increase following exposure to TGF-ß1. Quantitative RT-PCR confirmed a significant increase in the miR-143-3p/145-5p cluster in TGF-ß1-supplemented cultured podocytes and demonstrated upregulation of miR-143-3p in the glomeruli of mice with type 2 diabetes. Ectopic expression of miR-143-3p and miR-145-5p suppressed WT1 expression in cultured podocytes. Furthermore, inhibition of Smad or mammalian target of rapamycin signaling each partially reversed the TGF-ß1-induced increase in miR-143-3p/145-5p and decrease in WT1. In conclusion, TGF-ß1 induces expression of miR-143-3p/145-5p in part through Smad and mammalian target of rapamycin pathways, and miR-143-3p/145-5p reduces expression of WT1 in cultured human podocytes. miR-143-3p/145-5p may contribute to TGF-ß1-induced podocyte injury.NEW & NOTEWORTHY This study by miRNA microarray analysis demonstrated that miR-143-3p expression was upregulated in cultured human podocytes following exposure to transforming growth factor (TGF)-ß1. Furthermore, we report that the miR-143/145 cluster contributes to decreased expression of Wilms' tumor 1, which represents a possible mechanism for podocyte injury induced by TGF-ß1. This study is important because it presents a novel mechanism for TGF-ß-associated glomerular diseases, including diabetic kidney disease (DKD), and suggests potential therapeutic strategies targeting miR-143-3p/145-5p.


Asunto(s)
Diabetes Mellitus Tipo 2 , Nefropatías Diabéticas , MicroARNs , Podocitos , Factor de Crecimiento Transformador beta1 , Animales , Humanos , Ratones , Diabetes Mellitus Tipo 2/metabolismo , Nefropatías Diabéticas/metabolismo , MicroARNs/metabolismo , Podocitos/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Factor de Crecimiento Transformador beta1/metabolismo , Proteínas WT1/genética , Proteínas WT1/metabolismo
2.
Mod Rheumatol ; 32(5): 923-929, 2022 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-34915561

RESUMEN

OBJECTIVES: Otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) is a new category of otitis media in which cases of otitis media due to ANCA-associated vasculitis (AAV) are classified, regardless of ANCA variant or ANCA serotype. We aimed to describe the clinical features and course of patients with OMAAV and identify factors associated with hearing outcomes. METHODS: We retrospectively analysed 30 patients with OMAAV, classified based on the criteria proposed by the Japan Otological Society in 2016. RESULTS: Single-positive myeloperoxidase-ANCA, single-positive proteinase 3-ANCA, double-positive ANCA, and double-negative ANCA were identified in 47%, 33%, 7%, and 13% of the patients, respectively. All patients subjected to audiometry showed hearing impairments, and 85% were affected bilaterally. Mixed- and sensorineural-type hearing impairments were identified in 80% and 20% of impaired ears, respectively. Hypertrophic pachymeningitis (HPM) was identified in 37% of the patients. Immunosuppressive therapy was administered to 93% of patients, and the median air conduction hearing levels at pre- and post-treatment were 66.1 dB and 43.4 dB, respectively, indicating significant hearing improvements. HPM and a long interval between disease onset and treatment initiation were significantly correlated with poor hearing prognosis. CONCLUSIONS: OMAAV develops under any type of ANCA-serology and typically causes mixed or sensorineural bilateral hearing loss. The early initiation of immunosuppressive therapy and the absence of HPM were associated with good hearing outcomes.


Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos , Meningitis , Otitis Media , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Anticuerpos Anticitoplasma de Neutrófilos , Humanos , Mieloblastina , Otitis Media/complicaciones , Otitis Media/terapia , Peroxidasa , Estudios Retrospectivos
3.
Intern Med ; 57(21): 3135-3139, 2018 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-29877267

RESUMEN

Nivolumab is an anti-programmed cell death-1 (PD-1) antibody that is utilized as an immune checkpoint inhibitor (ICI) for cancer therapy. We herein present the case of a 57-year-old man who developed acute kidney injury during treatment with nivolumab for lung cancer. A renal biopsy revealed acute tubulointerstitial nephritis. Immunohistochemical staining demonstrated marked infiltration of macrophages and T cells together with mild B cell infiltration. Of note, strong CD163+ M2 macrophage infiltration was observed. The cessation of nivolumab and high-dose prednisolone therapy improved the renal function of the patient. Further, we review the pertinent literature on renal-infiltrating cells in ICI-induced tubulointerstitial nephritis.


Asunto(s)
Anticuerpos/inmunología , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/inmunología , Riñón/patología , Nefritis Intersticial/inducido químicamente , Nefritis Intersticial/patología , Nivolumab/efectos adversos , Nivolumab/inmunología , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/inmunología , Lesión Renal Aguda/patología , Antígenos CD/inmunología , Antígenos de Diferenciación Mielomonocítica/inmunología , Linfocitos B/inmunología , Linfocitos B/patología , Antígeno B7-H1/antagonistas & inhibidores , Antígeno B7-H1/inmunología , Humanos , Factores Inmunológicos/uso terapéutico , Riñón/inmunología , Neoplasias Pulmonares/tratamiento farmacológico , Macrófagos/inmunología , Macrófagos/patología , Masculino , Persona de Mediana Edad , Nefritis Intersticial/tratamiento farmacológico , Nefritis Intersticial/inmunología , Prednisolona/uso terapéutico , Receptor de Muerte Celular Programada 1 , Receptores de Superficie Celular/inmunología , Linfocitos T/inmunología , Linfocitos T/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA